Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

o adequate exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

--Tables to follow--

CV THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS DATA

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

Revenues:

Product sales, net $25,
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... presentations of leading Immunologists, Principle Investigators, scientists in ... Charles J Malemud, Professor at Case Western Reserve ... delivering his keynote address on “The effects ... in production of matrix metalloproteinase-9”. Arya Biragyn, a ...
(Date:7/29/2014)... 30, 2014 “PharmaSphere: Emerging Biotech ... Venture Capital Funding” report provides in-depth analysis of ... equity and venture capital segments of the financial ... to have significant impact on the future of ... Furthermore, the report identifies regions of the world ...
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of atom-thick ... through a chemical process invented at Rice University. ... like a nanoscale building, with floors and walls that ... of two-dimensional materials: floors and walls of graphene oxide ... platelets. , The researchers say the foam could ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2
... Texas , May 13 U.S. Renal Care, Inc. ... that it is extending its previously announced cash tender offer, through ... shares of common stock of Dialysis Corporation of America (Nasdaq: ... City time, on June 1, 2010 , unless further ...
... , May 13 /PRNewswire-Asia/ -- A signing ceremony for ... (TJAB) and Genzyme Corporation was held in the,Tianjin Economic-Technological Development Area ... , , ... Zihe, President of TJAB and,President of Nankai University, He Shushan, Director ...
... Texas , May 13 Sergio Lopez , 18, of ... marrow-derived stem cells in lieu of traditional surgery to repair a broken bone ... as a non-union, is to implant a device, such as a screw or ... , , ...
Cached Biology Technology:U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 2U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 3Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 3
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... YORK, N.Y. Cornell University and the United Nations University ... health, governance and security of the African continent when it ... Nov. 13. The series is free and open to the ... will be Africas food system and its interactions with health ...
... Hospital of Pittsburgh of UPMC are participating in an international ... insulin in preventing or delaying the onset of type 1 ... researchers want to determine if one insulin capsule taken daily ... in relatives of people who are found to be at ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today ... demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement ... the frequency of disease flares over time, and ... in combination with standard of care in patients ...
Cached Biology News:First symposium of UN University-Cornell Africa Series to be held at UN 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 3HGS announces positive Phase 2 LymphoStat-B at ACR meeting 4
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Request Info...
Biology Products: